Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MBRX
MBRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MBRX News
Moleculin Biotech Files to Sell 6.37M Shares
17h ago
seekingalpha
Avaí Bio Initiates α-Klotho Cell Production Phase
3d ago
PRnewswire
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
3d ago
Newsfilter
Moleculin Biotech Reports FY EPS of -$28.42
Mar 19 2026
seekingalpha
U.S. Stocks Close Lower, Dow Jones Falls Over 300 Points
Feb 19 2026
Benzinga
U.S. Stocks Open Lower with Dow Down Over 250 Points
Feb 19 2026
Benzinga
Moleculin Biotech Exercises Warrants for $8.3M
Feb 19 2026
seekingalpha
Moleculin Biotech Reports Significant Progress
Feb 18 2026
stocktwits
Moleculin Biotech Reports Progress in Annamycin Clinical Trial
Feb 18 2026
Newsfilter
Moleculin Biotech Inc. Announces 40% Preliminary CRC Rate in Miracle Trial
Feb 18 2026
moomoo
Moleculin Launches CEO Corner Platform for Investor Insights
Feb 13 2026
Newsfilter
Moleculin Biotech's 2026 MIRACLE Trial Data Unblinding Expected
Jan 12 2026
Globenewswire
Moleculin Stock Falls 17% Despite Encouraging Phase 1 WP1066 Results for Pediatric Brain Tumors
Dec 17 2025
NASDAQ.COM
Moleculin's WP1066 Demonstrates Immune Response and Positive Safety Profile in Pediatric Brain Cancer Study
Dec 17 2025
NASDAQ.COM
Moleculin Biotech Increases Enrollment to 78% for MIRACLE Trial
Dec 09 2025
Globenewswire
Moleculin Biotech Increases Enrollment to 78% for MIRACLE Trial
Dec 09 2025
Newsfilter
Show More News
